Art Garfunkel is breaking the sound of silence around his experience with plaque psoriasis. | Art Garfunkel is breaking the ...
MedPage Today on MSN3d
Momentum for Oral Therapies to Treat Plaque PsoriasisImproved targeting of the molecular drivers of psoriasis has paved the way for new oral therapies that offer the potential ...
Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...
Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage ...
US Weekly on MSN2d
Art Garfunkel Breaks Silence on Long Standing Health Battle: ‘It Wasn’t Easy’Art Garfunkel, 83, opened up for the first time about his long standing battle with psoriasis, which recently forced him to ...
Sun Pharma’s head of biologics marketing Maureen Shannon said, “We are so honored to partner with Art Garfunkel to share his ILUMYA story and to bring greater awareness to the impact psoriasis has ...
Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.
Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug ...
Can-Fite BioPharma (CANF) initiated a pivotal phase 3 psoriasis study of its oral drug Piclidenoson with the U.S. Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback